Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

NCT04858256 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

T-Cell Neoplasm
Lymphoproliferative Disorders

Interventions

DRUG: Pacritinib

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]